Participant characteristics and buprenorphine dose. - Wikidata - awgldk - TriplyDB

Participant characteristics and buprenorphine dose.

Participant characteristics and buprenorphine dose.

http://www.wikidata.org/entity/Q35738688

about

Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.The design and analysis of multisite effectiveness trials: a decade of progress in the National Drug Abuse Clinical Trials Network Predictive factors for relapse in patients on buprenorphine maintenance.Buprenorphine dosing choices in specific populations: review of expert opinion.Buprenorphine for managing opioid withdrawal.Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.Advances in the delivery of buprenorphine for opioid dependence.Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia.

P2860

Q28082657-51D356CA-CA7B-486B-9621-0D50247F82FB Q33595868-23A6275B-E5AB-4D93-A168-B861E93855C2 Q34615753-9E5CA652-B7A1-4191-860C-69EB224CF433 Q35597594-0E07BAAA-7119-449B-9335-BF4A0C50950A Q37580637-3966480F-23E0-44CB-9F83-AE3F2B902D99 Q38885405-45E8B8AC-55E4-48F7-911C-A6B7455D443B Q38950890-FF150BDB-CA87-4DDF-9CD8-CE85FF0FC745 Q39702414-2BB9D75A-9F28-4121-B2A0-9F63D45D2823 Q45946172-AB6584C9-5623-4620-A308-4CC043F17917 Q48152785-25AF6EBE-5ED2-4222-A859-668944147CFF

P2860

Participant characteristics and buprenorphine dose.

http://www.wikidata.org/entity/Q35738688

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Participant characteristics and buprenorphine dose.

@ast

Participant characteristics and buprenorphine dose.

@en

type

label

Participant characteristics and buprenorphine dose.

@ast

Participant characteristics and buprenorphine dose.

@en

prefLabel

Participant characteristics and buprenorphine dose.

@ast

Participant characteristics and buprenorphine dose.

@en

P1433

Q35738688-1AA058BE-D258-4532-86C3-B74DF331A135

P1476

Q35738688-764BE70B-111D-4618-9AB5-6603C3E2946D

P2093

Q35738688-09EA88D7-9D25-4B70-8F4C-82DE09C728DC

Q35738688-390631D5-3C83-4D3D-A090-0CA1CA09E53B

Q35738688-406FA020-A730-4C66-A484-CF3884D8D2F5

Q35738688-5B8B3E3D-13AB-4282-9FF6-AA4BCC9D1EF1

Q35738688-ADB83313-BB97-4D1F-A29D-F4EE59C98B2D

Q35738688-FB21A970-F749-4B9D-9418-09D3A51F4F6F

P2860

Q35738688-05F8A4D1-5150-4BD2-97EF-B06785D1400A

Q35738688-06E1F189-694D-48F7-AC07-DAF161F82CE2

Q35738688-3EF4CAA9-D4B9-4420-8A20-CC1A2C560550

Q35738688-3F8B44A0-B759-4380-95DB-22C8EBD09646

Q35738688-4105A2B6-9B43-495F-B510-EA9F2DD2BF9F

Q35738688-4242B90B-1A70-4428-ABB3-7E6F16C08B7D

Q35738688-4AD628BC-B2D3-4BAB-A601-6CA00D39AC39

Q35738688-556E1C92-E1A5-4AC5-953F-DF33F65A6A88

Q35738688-682B8DD1-0FC9-4A5F-82BB-2EB73675680D

Q35738688-6C74E695-AE0E-46F4-BFD1-C3B580C9023A

P304

Q35738688-A0A1519B-E2F5-4855-9E5C-077711867B66

P31

Q35738688-DD6178FA-11A0-4BCD-B246-8DC406E4B103

P356

Q35738688-1C3423F0-60FC-4A4D-BEAD-642855F41424

P433

Q35738688-20154013-5E34-4E62-A29C-1782C35DED11

P478

Q35738688-ED6F50D2-AA72-41EA-A39B-F779340C342B

P577

Q35738688-1548F37A-86FA-4DAF-A8F2-E57ACDB139FA

P5875

Q35738688-CD38A509-C5BC-4364-AA9D-936AF5BD8EB4

P698

Q35738688-7B277002-13BC-4C4F-AF89-1C675DE22E35

P932

Q35738688-FDF1C484-8388-48C5-8953-56BB03B9614D

P356

00952990.2011.596974

P1433

American Journal of Drug and Alcohol Abuse

P1476

Participant characteristics and buprenorphine dose.

@en

P2093

Albert Hasson

http://www.w3.org/2001/XMLSchema#string

Catherine P Canamar

http://www.w3.org/2001/XMLSchema#string

Christie Thomas

http://www.w3.org/2001/XMLSchema#string

Geetha Doraimani

http://www.w3.org/2001/XMLSchema#string

Maureen Hillhouse

http://www.w3.org/2001/XMLSchema#string

Walter Ling

http://www.w3.org/2001/XMLSchema#string

P2860

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network

Double-blind randomized trial of buprenorphine and methadone in opiate dependence.

Practical considerations for the clinical use of buprenorphine.

Buprenorphine: blending practice and research.

Clinical efficacy of buprenorphine: comparisons to methadone and placebo.

Buprenorphine tapering schedule and illicit opioid use.

The Clinical Opiate Withdrawal Scale (COWS).

Office-based buprenorphine treatment for opioid-dependent patients.

Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence.

Treatment effectiveness score as an outcome measure in clinical trials.

P304

453-459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00952990.2011.596974

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51583360

http://www.w3.org/2001/XMLSchema#string

P698

21854290

http://www.w3.org/2001/XMLSchema#string

P932

3272773

http://www.w3.org/2001/XMLSchema#string